Related references
Note: Only part of the references are listed.Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
Robert R. Henry et al.
DIABETES CARE (2018)
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
Julio Rosenstock et al.
DIABETES CARE (2018)
Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin
Robert Henry et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Cardiometabolic Multimorbidity With Mortality The Emerging Risk Factors Collaboration
Emanuele Di Angelantonio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Andy Menke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
Robert R. Henry et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes
Robert R. Henry et al.
CLINICAL THERAPEUTICS (2013)
Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
Robert R. Henry et al.
DIABETES CARE (2013)
Meta-analysis of individual participant data: rationale, conduct, and reporting
Richard D. Riley et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Design and analysis of non-inferiority mortality trials in oncology
M Rothmann et al.
STATISTICS IN MEDICINE (2003)